Clinical Trial Update: A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer [Phase 2]

View source ↗

Summary

Phase II trial update evaluating bevacizumab plus erlotinib in Krebs cycle altered cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Solid Tumors, Advanced Solid Tumors | Phase 2 | Status: UNKNOWN